about
Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individualsHIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells.Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery.Establishment and Replenishment of the Viral Reservoir in Perinatally HIV-1-infected Children Initiating Very Early Antiretroviral TherapyShort-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy.Identification of Siglec-1 null individuals infected with HIV-1.Antiretroviral therapy suppressed participants with low CD4+ T-cell counts segregate according to opposite immunological phenotypesViral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers.Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of antiretroviral therapy suppressed patients.Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery.Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated CellsEffectiveness of antitussives, anticholinergics or honey versus usual care in adults with uncomplicated acute bronchitis: a study protocol of an open randomised clinical trial in primary care
P50
Q34612385-A0592C77-099C-47C4-80EC-B1E269E0956CQ34669697-7A049710-E3FD-46C8-BA5B-FFC944F2F9BDQ35856740-9C56AFDA-036E-4FA5-AA82-2A7198ECCF3FQ36030494-9ACA3B8D-2658-421F-B532-B896D17BAD86Q36597778-8F969ED9-085F-44DA-9AB6-A113C1670869Q37181228-72C04211-8103-4ABB-A5BE-0DD65979F4D8Q37244544-35A9F8E4-320F-40EF-B6E0-C8549B43B1A5Q39525851-EFBE56D0-A8B2-4BB5-8816-8ACAE1ED0F59Q40920006-CF9AA020-EB9E-4D18-9810-55BB7CB310AEQ41723420-7A06C362-573A-4B15-AA62-E96A81728014Q42172595-3A52BC9F-EDBC-446C-941E-EEF7C3BBF87BQ42258099-B9292BAC-8CA2-45B7-B3C0-E008531B2D16Q61811646-C45BE31A-40A4-4751-9745-102CC9DC1A60Q92124556-A7A9432A-A4DA-4547-9D6E-1A90C7C35EA4
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Dan Ouchi
@ast
Dan Ouchi
@en
Dan Ouchi
@es
Dan Ouchi
@nl
Dan Ouchi
@sl
type
label
Dan Ouchi
@ast
Dan Ouchi
@en
Dan Ouchi
@es
Dan Ouchi
@nl
Dan Ouchi
@sl
prefLabel
Dan Ouchi
@ast
Dan Ouchi
@en
Dan Ouchi
@es
Dan Ouchi
@nl
Dan Ouchi
@sl
P108
P106
P31
P496
0000-0002-8630-152X